How Should Buyers Plan First Article Evidence for a New Injection Mold?

01

Set the evidence objective before the mold trial

An injection molding FAI should support a named decision: whether the current design, tool condition, material and trial process have supplied enough evidence for the next agreed gate. It is not automatically production qualification, regulatory approval, or approval of all future runs. State its purpose in the quality plan or purchase order so buyer and supplier use the same release definition.

Start with the released CAD model and drawing revision, then create a marked characteristic list. Separate critical-to-function dimensions, interfaces, safety or compliance-related features, cosmetic zones and ordinary dimensions. Include implicit model requirements when model-based definition is used. Boeing’s published FAI guidance likewise calls for accounting for all design characteristics and determining objective evidence for each one [3].

Every submitted article should be identifiable by sample group, mold and cavity where relevant, resin grade and lot, color system, trial stage and date. Label provisional conditions as provisional. This stops an engineering-learning part being mistaken for an approval-baseline part.

02

Build a sample matrix rather than relying on one good part

Define sample coverage before the trial. For a multi-cavity mold, say whether every cavity needs dimensional, visual, functional or weight evidence, and how samples are linked to cavity. For insert molding or overmolding, identify the insert, interface and assembly condition that the evidence must represent. The quantities below are an example format only; actual sample counts and acceptance limits must be confirmed for the project.

Keep sample groups separate when a relevant setting, resin lot, tool condition, color, texture or secondary operation changes. Agree cosmetic viewing distance, lighting, surface zone and reference standard before shipment. Photos help communication, but do not replace an agreed physical comparison or documented visual method.

03

Make dimensional evidence decision-ready

Map every reported value to the controlled drawing or model requirement. A ballooned drawing or characteristic extract should link nominal, tolerance, actual value, sample identity, method and pass/fail result. Report cavity identity where it matters. For GD&T features, record the datum strategy; isolated coordinates may not be reproducible.

Agree whether a characteristic needs CMM inspection, a gauge or fixture, or a functional test. Functional performance does not replace a specified dimensional result unless the buyer accepts it. NIST defines metrological traceability as a documented, unbroken chain of calibrations to a reference, with each step contributing to uncertainty, and notes that traceability alone does not guarantee fitness for purpose [2]. For sensitive features, ask for the method, resolution, calibration status, fixture arrangement and relevant uncertainty information.

Preserve out-of-tolerance results. The package should show the affected sample group and whether the outcome needs a tool correction, drawing review, concession request or repeat trial. Removing inconvenient data prevents a defensible release decision.

04

Use T1 samples within a controlled validation path

Injection molding T1 samples can verify steel-safe corrections, fill balance, ejection marks, gate vestige, shrink assumptions and cosmetic behavior. They should be identified as the specific T1 condition, not presented as proof of final production capability. Record incorporated tool or DFM changes and the open risks.

Separate part conformity from process evidence. Conformity asks whether submitted pieces meet the agreed drawing, appearance, material and functional requirements. Process evidence asks whether they were made under an identified proposed process window. A buyer can accept the first while seeking further evidence before production release, particularly for high-risk or multi-cavity programs.

FDA’s process-validation guidance, although written for regulated products, offers a useful evidence model: a written protocol specifies conditions, controls, collected data, tests, acceptance criteria, sampling, statistical approach and deviation handling [1]. Apply only the level appropriate to the product and contract; do not imply that every molded part needs pharmaceutical validation.

05

Control changes and close the approval decision

Define what invalidates all or part of the package: for example, a drawing revision, resin grade change, cavity repair, gate or cooling change, texture change, tool relocation, revised process setting, new measurement method or secondary-operation change. A targeted recheck may be enough, but its scope should be justified and documented.

Boeing’s FAI guidance calls for a documented change review and a full or partial FAI decision when engineering, production-process or tooling changes invalidate prior results [3]. This is a practical B2B principle even where aerospace forms are not a contract requirement.

The approval record should name the evidence reviewed, approved revision, conditions, deviations or concessions, corrective actions, residual risks and release scope. Use precise statuses such as approved for next trial, approved for pilot, conditionally approved pending named evidence, or not approved. For cross-border teams, also define document language, review timing, sample IDs and signed disposition format.

06

Bring the plan into the RFQ and release review

At RFQ, specify whether you need a first article injection molding report, customer FAI form, dimensional results, material documentation, cavity-level identification, functional testing support, photos, retained samples or pilot-run data. Provide the revision-controlled drawing and model, cosmetic criteria, mating parts or fixtures, and decision milestones. This makes the evidence scope quotable before tool build.

At release, compare the submission to the agreed matrix instead of judging only the best part in the box. Send your drawing package, target-market requirements, expected annual volume and desired decision gate with your inquiry. InjeForm can review the requested evidence scope alongside moldability and tooling questions; project-specific tests, quantities, lead time and acceptance criteria must be confirmed before work begins.